A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations ...

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new study says. Taking 160 milligrams of aspirin a day cuts the risk of cancer ...

"Aspirin 160 mg reduced recurrence by more than 50% in colorectal cancer patients with tumors harboring mutations in the PI3 kinase pathway," said Martling. "This is the first trial to show that ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 ...

Research reveals promising advancements of Ce6-GFFY in colorectal cancer treatment. Colorectal cancer (CRC) is a highly ...

Likewise, patients with other PI3K mutations had a 58% lower risk of cancer recurrence if they took aspirin -– 7.7% for those patients versus 16.8% for those given placebo tablets. Overall ...

Pfizer’s metastatic colorectal cancer (mCRC ... the combination in mCRC patients living with a BRAF V600E mutation who are treatment-naive. The top-line data also saw statistically significant ...